Jaguar Health (NASDAQ:JAGX) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Jaguar Health (NASDAQ:JAGX) from a buy rating to a hold rating in a research note released on Thursday, Zacks.com reports.

According to Zacks, “Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its product pipeline consists of Mytesi(R), Canalevia(TM), Equilevia(TM) and Neonorm (TM). Jaguar Health Inc., formerly known as Jaguar Animal Health Inc., is based in San Francisco, United States. “

Other equities research analysts have also issued reports about the stock. HC Wainwright set a $10.00 target price on shares of Jaguar Health and gave the stock a buy rating in a report on Tuesday, July 2nd. ValuEngine raised shares of Jaguar Health from a hold rating to a buy rating in a report on Thursday, August 1st.

Shares of Jaguar Health stock opened at $1.11 on Thursday. The firm has a market capitalization of $6.08 million, a PE ratio of -0.01 and a beta of 0.66. The company has a current ratio of 0.35, a quick ratio of 0.18 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average is $2.56 and its 200 day moving average is $1.44. Jaguar Health has a 1 year low of $1.00 and a 1 year high of $175.00.

Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings results on Tuesday, May 21st. The biotechnology company reported ($12.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($13.29) by $0.70. Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 826.41%. The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $2.20 million. As a group, research analysts anticipate that Jaguar Health will post -6.07 earnings per share for the current year.

In other Jaguar Health news, Director James J. Bochnowski bought 180,582 shares of Jaguar Health stock in a transaction on Tuesday, July 23rd. The shares were purchased at an average cost of $2.00 per share, with a total value of $361,164.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.81% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Featured Article: Ex-Dividend

Get a free copy of the Zacks research report on Jaguar Health (JAGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.